Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS:  Laura J. Esserman, MD, Read More

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. AUTHORS: Read More

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More

2020-06-15T18:02:53-07:00September 22nd, 2017|BluePrint, Evidence, Fatima, MammaPrint, Test Development|

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

PUBLICATION: Journal of Clinical Oncology 35, no. 24 (August 20, Read More

Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

PUBLICATION: Biomark Insights. 2016; 11: 139–146. doi: 10.4137/BMI.S38435 AUTHORS: Inès Read More

2020-06-15T18:43:57-07:00December 11th, 2016|Beumer, Biomarker Insights, Clinical Validation, Evidence, MammaPrint|

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. AUTHORS: Read More

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

PUBLICATION: N Engl J Med 2016; 375:717-729; DOI: 10.1056/NEJMoa1602253. AUTHORS: Read More

2020-06-15T18:44:47-07:00August 25th, 2016|Cardoso, Clinical Validation, Evidence, MammaPrint, MINDACT, NEJM|
Go to Top